...G. Lümmen; H. Sperling; H. Luboldt; T. Otto; H. Rübben Background: Treatment with biological response modifiers such as interferons resulted in reproducible responses in patients with renal cell carcinoma without proved benefit on survival and quality of life. Two trials were conducted to define...

... treatment or systemic therapy with interferon or cytostatic agents. The choice of therapy should be based on the specific needs of the individual patient. EKS-associated clinical symptoms, immunological status and other HlV-in-duced diseases, particularly opportunistic infections, influence the therapeutic...